Risk of immune ‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis

ConclusionsThis study demonstrates that compared with chemotherapy, PD ‐1 inhibitor may result in a higher risk of immune‐related pneumonitis. Nivolumab plus ipilimumab therapy had the highest pneumonitis risk. These findings could be taken into account by the physicians in decision making.

https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.2104?af=R

Source: Cancer Medicine - April 4, 2019 Category: Cancer & Oncology Authors: Yafang Huang, Haiyu Fan, Ning Li, Juan Du Tags: ORIGINAL RESEARCH Source Type: research